16 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
mission of providing impactful therapies to patients suffering from neurologic diseases.”
Recent Corporate Highlights:
AJ201 (Nrf1 and Nrf2 activator
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
shareholders and realize our mission of providing impactful therapies to patients suffering from neurologic diseases.”
Recent Corporate Highlights:
AJ201
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
10 Aug 23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:20pm
. We look forward to providing updates as we continue to advance these much-needed drugs for patients in the coming months, and execute on our mission
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
17 Apr 23
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
4:06pm
-101 for epilepsy and acute anxiety. Avenue continues to stay true to its mission of developing impactful therapies to treat patients with rare
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
16 Feb 22
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
7:39am
pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids
8-K
EX-99.1
6m8zqpbu8iaq 1gsrg
14 Jun 21
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
9:00am
8-K
EX-99.1
40cyrtyfk p4zsa6n
17 Dec 20
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
9:02am
8-K
EX-99.1
jwi0yp7f7fbpa1lob
13 Oct 20
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
6:10am
8-K
EX-99.1
ujf2ez85
14 Aug 20
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
8:30am
DEFA14A
ii3sn3y sg1
29 May 20
Additional proxy soliciting materials
9:30am
8-K
EX-99.1
z67 4sasp7i
11 May 20
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
9:00am
8-K
EX-99.1
lx8qb a5sdsrg
23 Apr 20
Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters
9:00am
8-K
EX-99.1
rxqn vw9do
30 Mar 20
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
9:01am
8-K
EX-99.1
br1bfktnr716fq6azfj2
13 Feb 20
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA
9:15am
8-K
EX-99.1
uj9myr3
11 Dec 19
Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol
9:00am
8-K
EX-99.1
9ur7 s9gq7
4 Nov 19
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
9:00am
- Prev
- 1
- Next